Xencor (XNCR) to Release Earnings on Thursday

Xencor (NASDAQ:XNCR - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Xencor to post earnings of ($0.60) per share and revenue of $23.44 million for the quarter.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts' expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xencor Stock Performance

Shares of XNCR stock traded up $0.40 during trading on Friday, hitting $11.26. The company's stock had a trading volume of 1,057,567 shares, compared to its average volume of 621,441. The company has a market cap of $801.17 million, a PE ratio of -3.52 and a beta of 0.99. Xencor has a 52 week low of $7.16 and a 52 week high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $11.31 and a 200-day moving average of $18.07.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Xencor in a report on Wednesday. William Blair assumed coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $32.86.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.